OL-008 The Diagnostic and prognostic significance of intrahepatic transforming growth factor-β1, angiotensin converting enzyme-2, alpha smooth muscle actin and endoglin in liver fibrosis associated chronic HCV infection

Abstract

Results: 43.9% of patients achieved a rapid virological response (RVR) and 69.1% of patients had a complete early virological response (cEVR). The serum alanine aminotransferase (ALT) normalization rates were 70.9% and 86.2% at week 4 and 12. Analyzing IL-28B variation (rs12979860), more proportions of patients with the CC genotype (46.7% or 75.3%) achieved a RVR or a cEVR respectively, compared to patients with the CT/TT genotypes (23.8% or 35.3%). However, in a multivariable logistic regression model, the IL-28B genotype was not shown statistically to be a predictive value for RVR or cEVR. Baseline predictive factors for RVR included the serum HCV RNA <4×105 IU/mL (OR: 0.16) and gender (in females, OR: 0.39). The HCV genotype was only a predictive factor for cEVR (2a vs 1b, OR: 8.80). The treatments for 28 patients were discontinued due to adverse events such as anaemia and fatigue. Conclusion: The recombinant IFNa-2b therapy demonstrated a potent anti-virus effect and a significant biochemical improvement. It has good tolerance and safety profiles. The serum HCV RNA, gender and the HCV genotype were identified as valuable predictors for patients who responded to IFN/RBV treatments in the present study.